RSV Vaccine Sales Decline Sharply in U.S. Amid Narrowed Eligibility

GSK and Pfizer face significant drop in demand as regulatory changes limit vaccine recipients to older adults and those at higher risk.

U.S. sales of GSK and Pfizer's RSV vaccines have decreased significantly due to a narrowed target group and a one-time vaccination recommendation.
Demand for RSV vaccines has fallen by up to two-thirds compared to the previous year, according to data from healthcare analytics firm IQVIA.
Regulatory changes now recommend the vaccine for adults aged 75 and older, and those aged 60 to 74 with increased risk due to medical conditions.
GSK's Arexvy remains the market leader, though its sales are expected to dip slightly this year, while Pfizer's Abrysvo is projected to see a sales increase.
GSK reported that Arexvy maintains 43% effectiveness against severe RSV in its third year, as the company explores re-vaccination potential.